Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Camp4 Therapeutics (CAMP) EBIT (2023 - 2025)

Historic EBIT for Camp4 Therapeutics (CAMP) over the last 3 years, with Q3 2025 value amounting to -$13.7 million.

  • Camp4 Therapeutics' EBIT fell 99.88% to -$13.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$53.8 million, marking a year-over-year decrease of 244.44%. This contributed to the annual value of -$53.1 million for FY2024, which is 233.04% down from last year.
  • Latest data reveals that Camp4 Therapeutics reported EBIT of -$13.7 million as of Q3 2025, which was down 99.88% from -$13.0 million recorded in Q2 2025.
  • In the past 5 years, Camp4 Therapeutics' EBIT registered a high of -$12.3 million during Q3 2023, and its lowest value of -$14.0 million during Q4 2024.
  • Moreover, its 3-year median value for EBIT was -$13.1 million (2025), whereas its average is -$13.2 million.
  • Its EBIT has fluctuated over the past 5 years, first tumbled by 954.77% in 2024, then plummeted by 99.88% in 2025.
  • Camp4 Therapeutics' EBIT (Quarter) stood at -$13.5 million in 2023, then dropped by 4.14% to -$14.0 million in 2024, then increased by 2.73% to -$13.7 million in 2025.
  • Its EBIT was -$13.7 million in Q3 2025, compared to -$13.0 million in Q2 2025 and -$13.1 million in Q1 2025.